Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00696423
First received: June 5, 2008
Last updated: November 21, 2012
Last verified: November 2012

June 5, 2008
November 21, 2012
June 2008
July 2008   (final data collection date for primary outcome measure)
  • Anti-polyribosyl-ribitol-phosphate (PRP) Antibody Concentrations [ Time Frame: One month after booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in microgram per milliliter (μg/mL).
  • Anti-diphtheria Toxoid Antibody Concentrations [ Time Frame: One month after booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in international Unit per milliliter (IU/mL).
  • Anti-tetanus Toxoid Antibody Concentrations [ Time Frame: One month after booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in IU/mL.
  • Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibody Concentrations [ Time Frame: One month after booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in Enzyme-Linked Immuno Sorbent Assay (ELISA) unit per milliliter (EL.U/mL).
  • The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies [ Time Frame: One month after booster vaccination ] [ Designated as safety issue: No ]
    Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.
  • Anti-polyribosyl-ribitol-phosphate (PRP) antibody concentrations [ Time Frame: One month after booster vaccination ]
  • Anti-diphtheria toxoid antibody concentrations [ Time Frame: One month after booster vaccination ]
  • Anti-tetanus toxoid antibody concentrations [ Time Frame: One month after booster vaccination ]
  • Anti-pertussis toxoid (PT), anti-filamentous haemagglutinin (FHA) and anti-pertactin (PRN) antibody concentrations [ Time Frame: One month after booster vaccination ]
  • Anti-PRP, anti-diphtheria, anti-tetanus, anti-PT, anti-FHA, and anti-PRN antibody concentrations [ Time Frame: One month after booster vaccination ]
Complete list of historical versions of study NCT00696423 on ClinicalTrials.gov Archive Site
  • Anti-PRP Antibody Concentrations [ Time Frame: Before booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in μg/mL.
  • Anti-diphtheria Toxoid Antibody Concentrations [ Time Frame: Before booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in IU/mL.
  • Anti-tetanus Toxoid Antibody Concentrations [ Time Frame: Before booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in IU/mL.
  • Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations [ Time Frame: Before booster vaccination ] [ Designated as safety issue: No ]
    Geometric mean concentrations are given in EL.U/mL.
  • The Number of Subjects Seroprotected for Anti-PRP, Anti-diphtheria and Anti-tetanus Antibodies and Seropositive for Anti-PT, Anti-FHA and Anti-PRN Antibodies [ Time Frame: Before booster vaccination ] [ Designated as safety issue: No ]
    Assay cut-offs indicating seroprotection or seropositivity for the different antigens were the following: anti-PRP antibody concentrations ≥ 0.15 µg/mL, anti-diphtheria and anti-tetanus antibody concentrations ≥ 0.1 IU/mL, anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 20 EL.U/mL.
  • Number of Subjects Reporting Solicited Local and General Symptoms [ Time Frame: During the 4-day follow-up period after booster vaccination ] [ Designated as safety issue: Yes ]
    Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever, irritability, and loss of appetite.
  • Number of Subjects Reporting Unsolicited Adverse Events (AE) [ Time Frame: During the 31-day follow-up period after booster vaccination ] [ Designated as safety issue: No ]
    An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
  • Number of Subjects Reporting Serious Adverse Events (SAE) [ Time Frame: During the 31-day follow-up period after booster vaccination ] [ Designated as safety issue: No ]
    An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in isability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
  • Anti-PRP antibody concentrations [ Time Frame: Before booster vaccination ]
  • Anti-diphtheria toxoid antibody concentrations [ Time Frame: Before booster vaccination ]
  • Anti-tetanus toxoid antibody concentrations [ Time Frame: Before booster vaccination ]
  • Anti-PT, anti-FHA and anti-PRN antibody concentrations [ Time Frame: Before booster vaccination ]
  • Anti-PRP, anti-diphtheria, anti-tetanus, anti-PT, anti-FHA and anti-PRN antibody concentrations [ Time Frame: Before booster vaccination ]
  • Occurrence of solicited local and general symptoms [ Time Frame: During the 4-day follow-up period after booster vaccination ]
  • Occurrence of unsolicited symptoms [ Time Frame: During the 31-day follow-up period after booster vaccination ]
  • Occurrence of serious adverse events (SAEs) [ Time Frame: Following booster vaccination ]
Not Provided
Not Provided
 
Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children
Immunogenicity and Reactogenicity Study of GlaxoSmithKline Biologicals' Infanrix™/Hib Vaccine Administered as a Booster Dose to 18-24 Months Old Children

This protocol posting deals with objectives & outcome measures of the booster phase. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00412854). This Phase IIIB study will compare GSK Biologicals' DTPa/Hib vaccine to separately administered DTPa and Hib vaccines in Chinese children 18 to 24 months of age, in terms of safety and immunogenicity.

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Haemophilus Influenzae Type b Disease
  • Diphtheria
  • Pertussis
  • Tetanus
  • Biological: Infanrix™
    Intramuscular injection, one dose
  • Biological: Hiberix™
    Intramuscular injection, one dose
  • Experimental: Infanrix/Hib Single Injection Group
    Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.
    Interventions:
    • Biological: Infanrix™
    • Biological: Hiberix™
  • Active Comparator: Infanrix + Hiberix Separate Injection Group
    Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.
    Interventions:
    • Biological: Infanrix™
    • Biological: Hiberix™
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
467
July 2008
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
  • Subjects should have completed the full three-dose primary vaccination course in study 104567.
  • A male or female child between, and including, 18 and 24 months of age at the time of the booster vaccination.
  • Written informed consent obtained from the parent or guardian of the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding booster vaccination, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.
  • Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period, with the exception of measles or combined measles, mumps and rubella (MMR) vaccination.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Previous booster vaccination against diphtheria, tetanus, pertussis and/or Haemophilus influenzae type b diseases since the end of the primary study.
  • History of diphtheria, tetanus, pertussis and/or Haemophilus influenzae type b diseases.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s).
  • Major congenital defects or serious chronic illness.
  • History of any progressive neurological disorders or seizures.
  • Acute disease and/or fever at time of enrolment.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.
  • Occurrence of any of the following adverse events (AEs) after previous administration of a diphtheria-tetanus-pertussis (DTP) vaccine:

    • Hypersensitivity reaction due to any component of the vaccine.
    • Encephalopathy.
    • Fever ≥ 40.0 °C (axillary temperature) within 48 hours of vaccination.
    • Collapse or shock-like state within 48 hours of vaccination.
    • Persistent, inconsolable crying occurring within 48 hours of vaccination and lasting ≥ 3 hours.
    • Seizures with or without fever occurring within 3 days of vaccination.
Both
18 Months to 24 Months
Yes
Contact information is only displayed when the study is recruiting subjects
China
 
NCT00696423
111535
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP